FindTrial
Sign In

Edoxaban Monotherapy

DRUG2 trials

Sponsors

Gi-Byoung Nam, Asan Medical Center

Conditions

Acute Ischemic StrokeAnticoagulantAntiplateletAtrial FibrillationCoronary Artery AtherosclerosisCoronary Artery DiseaseExtracranial AtherosclerosisIntracranial Atherosclerosis

Phase 4

Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
CompletedNCT03718559
Gi-Byoung NamAtrial Fibrillation, Coronary Artery Disease, Stable Angina +1
Start: 2019-05-14End: 2023-11-08Updated: 2024-06-10

Unknown Phase

Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Active, not recruitingNCT04010955
Asan Medical CenterAcute Ischemic Stroke, Anticoagulant, Antiplatelet +5
Start: 2019-10-08End: 2026-06-27Target: 1200Updated: 2025-07-11

Related Papers

Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trial.
2026-04-20
Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial.
2026-03-18
Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial
Heart2025-09-09
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
New England Journal of Medicine2024-09-0163 citations